

Home

May 2026

your

Prague, Czech Republic, 14-17

[LEARN MORE](#)

Save the date

Expand
knowledge

Claim your CME credits

[LEARN MORE](#)

ITALY, 6 - 8

8TH INTERNATIONAL CONGRESS ON VENICE,
MARCH 2025

KEEP ME UPDATED

SAVE THE DATE Join us
in Venice |
26-28 March 2025

us in Venice | 26-28 March 2025

Keep me updated Join

Connect with the community

CORA 2025 will take place in Venice, Italy from 6-8 March 2025 and is an excellent forum to discuss the controversies in rheumatology & autoimmunity. Ongoing debate among professionals on the topics of treatment, diagnosis, and translating research into practice is essential for addressing these controversies and advancing knowledge in the field.

Why Attend

Inspire your tomorrow: the transformative benefits of attending CORA 2025

[mvc_infobox info_style="mega_info_box_2" info_opt="show_icon" icon_size="24" title_color="#ffffff" font_icon="fas fa-arrow-alt-circle-right" icon_color="#bcd75e" icon_bg="#ffffff"]Be the first to **witness groundbreaking research** in rheumatology and autoimmunity at CORA 2025.[/mvc_infobox][mvc_infobox info_style="mega_info_box_2" info_opt="show_icon" icon_size="24" title_color="#ffffff" font_icon="fas fa-arrow-alt-circle-right" icon_color="#bcd75e" icon_bg="#ffffff"]Engage in **thought-provoking debates** on key controversies in rheumatology and autoimmunity.[/mvc_infobox][mvc_infobox info_style="mega_info_box_2" info_opt="show_icon" icon_size="24" title_color="#ffffff" font_icon="fas fa-arrow-alt-circle-right" icon_color="#bcd75e" icon_bg="#ffffff"]**Meet key opinion leaders** and gain insights that can advance your career.[/mvc_infobox][mvc_infobox info_style="mega_info_box_2" info_opt="show_icon" icon_size="24" title_color="#ffffff" font_icon="fas fa-arrow-alt-circle-right" icon_color="#bcd75e" icon_bg="#ffffff"]**Connect** with colleagues and build lasting professional relationships.[/mvc_infobox][mvc_infobox info_style="mega_info_box_2" info_opt="show_icon" icon_size="24" title_color="#ffffff" font_icon="fas fa-arrow-alt-circle-right" icon_color="#bcd75e" icon_bg="#ffffff"]**Showcase your expertise**, present your research, and gain recognition in the field.[/mvc_infobox][mvc_infobox info_style="mega_info_box_2" info_opt="show_icon" icon_size="24" title_color="#ffffff" font_icon="fas fa-arrow-alt-circle-right" icon_color="#bcd75e" icon_bg="#ffffff"]

Earn up to **15 CME credits** and advance your career with expert

insights and takeaways.

```
[/mvc_infobox][mvc_infobox    info_style="mega_info_box_2"
info_opt="show_icon"    icon_size="24"    title_color="#ffffff"
font_icon="fas fa-arrow-alt-circle-right"    icon_color="#bcd75e"
icon_bg="#ffffff"]Discover the latest industry innovations and
advancements    in    rheumatic    and    autoimmune
treatments.[/mvc_infobox]
```

Inspire your tomorrow: the transformative benefits of attending CORA 2025

- Get the best out of the debates on controversies in rheumatology and autoimmunity
- Be the first to witness new scientific findings
- Meet key opinion leaders
- Showcase your research and expertise
- Explore the industry innovations
- Network with colleagues

Register Today

Join the conversation

Download the App

Elevate your congress experience

Earn up to 15 CME Credits

Expand your knowledge

CORA 2025 Highlights

Debate 3

LN Treatment: Early Combination vs. Standard Treatment

Ioannis Parodis,
Sweden

EARLY COMBINATION

Laurent Arnaud,
France

STANDARD TREATMENT

Debate 21

Transition From Psoriasis to Psoriatic Arthritis: Are We Getting Closer?

Alen Zabotti,
Italy

YES

Dennis McGonagle,
UK

NO

Venice will enchant you

Maximize both your professional and personal experience. Dive into groundbreaking research and debate the latest advancements at the 8th

International Congress on Controversies in Rheumatology & Autoimmunity. After a busy Congress day, unwind by exploring Venice—stroll through St. Mark's Square, take a magical gondola ride, savor traditional cuisine, and soak in the vibrant atmosphere of this incredible city.

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

CORA 2025 Debates

Explore all 21 debates. Join us and voice your opinion.

Debate 1

March 6, 2025, 13:00-14:00 (CET)

What Should We Use As the First-Line Treatment for RA?

b/tsDMARDs: Zoltan Szekanecz

MTX: Andrea Rubbert-Roth

Debate 2

March 6, 2025, 13:00-14:00 (CET)

Are the New Classification Criteria a Step Forward in the Management of Antiphospholipid Syndrome?

Yes: Savino Sciascia

No: Jaume Alijotas-Reig

Debate 3

March 6, 2025, 14:10-15:10 (CET)

LN Treatment: Early Combination vs. Standard Treatment

Early Combination: Ioannis Parodis

Standard Treatment: Laurent Arnaud

Debate 4

March 6, 2025, 14:10-15:10 (CET)

The Use of Medical Cannabis in Rheumatic Pain Management: Valid Option or Unproven treatment?

Valid Option: Howard Amital

Unproven Treatment: Winfried Häuser

Debate 5

March 7, 2025, 9:05-10:05 (CET)

Beyond Physical Examination – How to Approach to RA Management: Joint Ultrasound or Synovial Biopsy?

Joint Ultrasound: Maria-Antonietta D'Agostino

Synovial Biopsy: Felice Rivellese

Debate 6

March 7, 2025, 9:05-10:05 (CET)

Mepolizumab in EGPA: Does One Size Fit All?

Yes: Benjamin Terrier

No: Giacomo Emmi

Debate 7

March 7, 2025, 10:45-11:45 (CET)

TNFi or IL17i for the Slowing the Radiographic Progression in Spondyloarthritis?

TNFi: Mikkel Østergaard

IL17i: Salvatore D'Angelo

Debate 8

March 7, 2025, 10:45-11:45 (CET)

Gut Microbiome in Rheumatic Diseases: Revolutionary or Fake News?

Revolutionary: Francesco Ciccia

Fake News: Zoltan Szekanecz

Debate 9

March 7, 2025, 11:50-12:50 (CET)

CAR-T Cells in Rheumatic Diseases: Game-Changer or Just a Buzz?

Game-Changer: Laura Bucci

Just a Buzz: Marit Stockfelt

Debate 10

March 7, 2025, 11:50-12:50 (CET)

Is Seronegative Sjogren Syndrome a Distinct Clinical Entity? & Should Hydroxychloroquine Be Used in Patients With Sjogren Syndrome?

Yes: Roberto Gerli

No: Athanasios Tzioufas

Debate 11

March 7, 2025, 15:10-16:10 (CET)

Early Biologic Treatment in Systemic Lupus: Necessary or Overemphasized?

Necessary: Mariele Gatto

Overemphasized: Chris Wincup

Debate 12

March 7, 2025, 15:10-16:10 (CET)

Is Hematopoietic Stem Cell Transplantation (Really) a Valid Option for Patients With Systemic Sclerosis?

Yes: Dominique Farge

No: Oliver Distler

Debate 13

March 7, 2025, 16:50-17:50 (CET)

Can We Give Targeted Therapies in Patients With Cancer?

Yes: Eden Sebbag

No: Zoltan Szekanecz

Debate 14

March 7, 2025, 16:50-17:50 (CET)

Are IPAF and UCTD Two Clinical Variants of the Same Systemic Autoimmune Disorder?

Two Clinical Variants: Marco Sebastiani

The Same: Szilvia Szamosi

Debate 15

March 7, 2025, 17:55-18:55 (CET)

Do JAK Inhibitors Aggravate Comorbidities Such As Cardiovascular Disease and Cancer?

Yes: Serena Bugatti

No: Ernest Choy

Debate 16

March 8, 2025, 9:00-10:00 (CET)

Should We Treat preRA/at Risk RA Individuals or Not?

Yes: Andrew Cope

No: György Nagy

Debate 17

March 8, 2025, 9:00-10:00 (CET)

Is It Common To Achieve the T2T Goals in SLE Patients?

Yes: Marta Mosca

No: Anisur Rahman

Debate 18

March 8, 2025, 11:10-12:10 (CET)

Axial Psoriatic Arthritis and axSpA: To Lump or to Split

To Lump: Philippe Sewerin

To Split: Ennio Lubrano

Debate 19

March 8, 2025, 11:10-12:10 (CET)

Should Immunosuppressive Drugs Be Used in All Patients With the Limited Cutaneous Form of SSc?

Yes: Marco Matucci-Cerinic

No: Yannick Allanore

Debate 20

March 8, 2025, 14:30-15:30 (CET)

Is It Safe to Use Low-Dose Glucocorticoids in GCA?

Yes: Francesco Muratore

No: Peter Villiger

Debate 21

March 8, 2025, 14:30-15:30 (CET)

Transition From Psoriasis to Psoriatic Arthritis: Are We Getting Closer?

Yes: Alen Zabotti

No: Dennis McGonagle

Stay in touch

Subscribe to our newsletter to make sure you never miss a deadline and receive the latest updates in your inbox.

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